DK1404363T3 - Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner - Google Patents

Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner

Info

Publication number
DK1404363T3
DK1404363T3 DK02739776T DK02739776T DK1404363T3 DK 1404363 T3 DK1404363 T3 DK 1404363T3 DK 02739776 T DK02739776 T DK 02739776T DK 02739776 T DK02739776 T DK 02739776T DK 1404363 T3 DK1404363 T3 DK 1404363T3
Authority
DK
Denmark
Prior art keywords
mucosal
adjuvant composition
adjuvant
injection vaccines
vaccines
Prior art date
Application number
DK02739776T
Other languages
English (en)
Inventor
Jay Dean Gerber
Original Assignee
Advanced Bioadjuvants Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Bioadjuvants Llc filed Critical Advanced Bioadjuvants Llc
Application granted granted Critical
Publication of DK1404363T3 publication Critical patent/DK1404363T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02739776T 2001-06-19 2002-06-11 Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner DK1404363T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/884,201 US6676958B2 (en) 2001-06-19 2001-06-19 Adjuvant composition for mucosal and injection delivered vaccines
PCT/US2002/018158 WO2002102305A2 (en) 2001-06-19 2002-06-11 Adjuvant composition for mucosal and injection delivered vaccines

Publications (1)

Publication Number Publication Date
DK1404363T3 true DK1404363T3 (da) 2011-07-25

Family

ID=25384162

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02739776T DK1404363T3 (da) 2001-06-19 2002-06-11 Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner

Country Status (10)

Country Link
US (6) US6676958B2 (da)
EP (1) EP1404363B1 (da)
JP (1) JP2004534798A (da)
AT (1) ATE507840T1 (da)
AU (1) AU2002312407B2 (da)
CA (1) CA2456864C (da)
DE (1) DE60239937D1 (da)
DK (1) DK1404363T3 (da)
ES (1) ES2363966T3 (da)
WO (1) WO2002102305A2 (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
JP5591434B2 (ja) 2002-12-20 2014-09-17 ゼリス ファーマシューティカルズ インコーポレイテッド 皮内注射方法
ZA200700457B (en) 2004-06-15 2008-08-27 New York Blood Ct Inc Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
US20080102073A1 (en) * 2006-10-30 2008-05-01 Wayne Koff Antigen-Antibody Complexes as HIV-1 Vaccines
US8105600B2 (en) * 2006-10-30 2012-01-31 International Aids Vaccine Initiative Method of inducing high-titer neutralizing antibody responses in a host by administering immune complexes comprising anti-HIV-1 Env antibodies and the HIV-1 Env
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
FR2922767B1 (fr) * 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
AU2008318677A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as HIV-1 vaccines
BRPI0913612B8 (pt) * 2008-06-05 2021-05-25 Immunovaccine Technologies Inc composição injetável de vacina, método para obter a composição e uso da composição
US9060926B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072799B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060931B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111835A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US8545855B2 (en) * 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545857B2 (en) * 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8721583B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US20100111834A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US20100111836A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US8793075B2 (en) * 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8603495B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8551505B2 (en) * 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050070B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111841A1 (en) * 2008-10-31 2010-05-06 Searete Llc Compositions and methods for surface abrasion with frozen particles
US8256233B2 (en) * 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8784385B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen piercing implements and methods for piercing a substrate
US9060934B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8725420B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050251B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8551506B2 (en) * 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
FR2957803B1 (fr) * 2010-03-24 2012-06-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Diluants adjuvants de vaccins vivants pour maladies porcines
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
BR112013023062B1 (pt) 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc Solução estável para a injeção parenteral e método de fabricação da mesma
EP2763698B1 (en) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
KR102007057B1 (ko) 2011-10-31 2019-08-02 엑스에리스 파머수티클스, 인크. 당뇨병 치료를 위한 제형물
EP2804626B1 (en) 2012-01-20 2019-05-01 Fernando Thome Kreutz Autologous cancer cell vaccine
CA3081072A1 (en) * 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
WO2014135521A1 (en) * 2013-03-08 2014-09-12 Li Galli B.V. Vaginal drug delivery and/or diagnostic system
US9539212B2 (en) * 2013-03-11 2017-01-10 Cristal Delivery B.V. Vaccination composition
WO2014174039A1 (en) * 2013-04-24 2014-10-30 Medizinische Universität Wien Novel vaccine formulation for ocular immunization
WO2015100409A2 (en) 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
AU2015300944B2 (en) 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
JP2018020962A (ja) * 2014-12-08 2018-02-08 エヌエーアイ株式会社 新規アジュバント
WO2016094602A1 (en) 2014-12-10 2016-06-16 Tufts University Vhh based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
CN110709061B (zh) 2017-06-02 2023-09-08 Xeris药物公司 抗沉淀的小分子药物制剂
CN107307429B (zh) * 2017-07-04 2020-09-22 北京英茂药业有限公司 益生菌制剂的薄膜包衣预混剂及其制备方法、应用
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
CN108671262B (zh) * 2018-07-06 2021-09-24 华南师范大学 一种栓塞剂及其制备方法和应用
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
KR20220128372A (ko) 2020-01-16 2022-09-20 얀센 파마슈티칼즈, 인코포레이티드 Fimh 돌연변이체, 이를 갖는 조성물 및 이의 용도
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
CN111893642B (zh) * 2020-08-10 2022-05-17 四川大学 一种卤胺类聚合物抗菌抗病毒纳米纤维膜及其制备方法
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
CA3207841A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc Fimh mutants, compositions therewith and use thereof
TW202304504A (zh) 2021-04-01 2023-02-01 美商詹森藥物公司 大腸桿菌ｏ１８生物軛合物之生產

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199561A (en) * 1979-02-26 1980-04-22 The Dow Chemical Company Coated nutrients and medicaments for veterinary use
JPS59159175A (ja) * 1983-03-02 1984-09-08 Konishiroku Photo Ind Co Ltd 圧力定着性マイクロカプセル型トナ−
US4740365A (en) * 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ZA881694B (en) * 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
US5565209A (en) * 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
US4932958A (en) * 1988-05-10 1990-06-12 American Medical Systems, Inc. Prostate balloon dilator
US4917892A (en) * 1988-06-28 1990-04-17 Temple University Encapsulated topical delivery system
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5132117A (en) * 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5550177A (en) 1992-02-28 1996-08-27 The United States Of America As Represented By The Secretary Of Agriculture Starch and poly (ethlene-co-acrylic acid) pastes and gels, and method for their making
WO1993024147A1 (en) * 1992-05-29 1993-12-09 Smithkline Beecham Corporation Lecithin adjuvanted modified live virus vaccines
US5352448A (en) * 1992-07-20 1994-10-04 Purdue Research Foundatioin Oral administration of antigens
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5500161A (en) * 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5451411A (en) * 1993-10-15 1995-09-19 University Of Washington Methods and compositions for the oral delivery of therapeutic agents
DK0678017T3 (da) * 1993-11-05 1998-10-19 Amgen Inc Liposomfremstilling og materialeindkapslingsfremgangsmåde
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
US5674495A (en) * 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
JP2001131087A (ja) * 1999-11-05 2001-05-15 Chemo Sero Therapeut Res Inst オイルアジュバントワクチン
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines

Also Published As

Publication number Publication date
US20080050395A1 (en) 2008-02-28
US8501221B2 (en) 2013-08-06
DE60239937D1 (de) 2011-06-16
EP1404363B1 (en) 2011-05-04
WO2002102305A2 (en) 2002-12-27
US6676958B2 (en) 2004-01-13
AU2002312407B2 (en) 2007-03-08
EP1404363A2 (en) 2004-04-07
ES2363966T3 (es) 2011-08-22
US20030003105A1 (en) 2003-01-02
WO2002102305A3 (en) 2003-04-03
US20120070453A1 (en) 2012-03-22
CA2456864C (en) 2014-06-10
AU2002312407A1 (en) 2003-01-02
US20030202979A1 (en) 2003-10-30
EP1404363A4 (en) 2004-11-24
WO2002102305B1 (en) 2003-05-08
ATE507840T1 (de) 2011-05-15
US20030211115A1 (en) 2003-11-13
US20040170640A1 (en) 2004-09-02
CA2456864A1 (en) 2002-12-27
US7879333B2 (en) 2011-02-01
JP2004534798A (ja) 2004-11-18

Similar Documents

Publication Publication Date Title
DK1404363T3 (da) Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner
NO20015073D0 (no) Vaksiner
DE60012711D1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
ATE433771T1 (de) Vorrichtung zur abgabe einer vakzine
NO20021431L (no) Intranasal influensavirus vaksine
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
WO2002034205A3 (en) Using heat shock proteins to increase immune response
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
WO2003066094A3 (en) Hepatitis b vaccines
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
WO2002087494A3 (en) Novel vaccine
DK1024824T3 (da) Dispergerende vaccinesammensætning i fast form til oral indgivelse
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
WO2003080111A3 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
AU6721801A (en) The use of plant oil-bodies in vaccine delivery systems
AR053661A1 (es) Peptido para entregar vacunas via mucosas
GB2444676A (en) Adjuvanted vaccine
EA200702079A1 (ru) Вакцина
RU2003137039A (ru) Способ ревакцинации взрослых людей против дифтерии и столбняка на крайнем севере